Peter G. Milner
Vorstandsvorsitzender bei AshHill Investments LLC
Profil
Peter G.
Milner is the founder of CV Therapeutics, Inc. (founded in 1992), Optivia Biotechnology, Inc. (founded in 2007), ARYx Therapeutics, Inc. (founded in 1997), Armetheon, Inc. (founded in 2011), and Renexxion LLC (founded in 2014).
He held various titles at these companies.
Dr. Milner is also the founder of Renexxion Ireland Ltd.
Dr. Milner's current job(s) include Chairman at AshHill Investments LLC, Director at Lifeline Technologies, Inc., Director at Ischemix, Inc., and Director at SinuSys Corp.Dr. Milner's former job(s) include Chief Executive Officer & Director at Heart Metabolics Ltd.
(2013-2015), Director at Trillium Therapeutics ULC, Director at California Healthcare Institute, Director at Retrotope, Inc., Assistant Professor at Washington University in St. Louis, Principal at ML Laboratories Plc, and Scientific Advisor at ABV LLC.
Dr. Milner obtained a doctorate degree from The University of Liverpool in 1980.
Aktive Positionen von Peter G. Milner
| Unternehmen | Position | Beginn |
|---|---|---|
Lifeline Technologies, Inc.
 Lifeline Technologies, Inc. BiotechnologyHealth Technology Lifeline Technologies, Inc. operates as a health sciences development company which focuses on novel strategies. It offers ChoLESStolife, a non-prescription and non-synthetic cholesterol absorption inhibitor for the reduction of human cholesterol using a fat-free delivery system for soy sterols and stanols. The company was registered by Curtis A. Spilburg and Richard E. Ostlund on October 1, 2002 and is headquartered in Hendersonville, NC. | Direktor/Vorstandsmitglied | - |
SinuSys Corp.
 SinuSys Corp. Medical SpecialtiesHealth Technology SinuSys Corp. develops medical device therapies to improve the sinus health of patients with chronic sinusitis. Its products include Vent-OS sinus dilation system, Restora steroid-eluting spacer, and SinuSys product pipeline. The company was founded by Jerome Hester and Thomas A. Schreck in 2010 and is headquartered in Palo Alto, CA. | Direktor/Vorstandsmitglied | - |
AshHill Investments LLC
 AshHill Investments LLC Investment ManagersFinance AshHill Investments LLC (AshHill Investments) is a venture capital firm founded in 2011. The firm is headquartered in Ft. Thomas, Kentucky. | Vorstandsvorsitzender | - |
Armetheon, Inc.
 Armetheon, Inc. Pharmaceuticals: MajorHealth Technology Armetheon, Inc. engages in medical development. It specializes in thrombosis and cardiac arrhythmias. The company was founded by Pascal J. Druzgala, Muralitharan Ken Kengatharan and Peter G. Milner in 2011 and is headquartered in Milpitas, CA. | Gründer | 01.01.2011 |
Optivia Biotechnology, Inc.
 Optivia Biotechnology, Inc. Pharmaceuticals: MajorHealth Technology Optivia Biotechnology, Inc. provides contract research organization offering drug transporter research services and solutions to biotechnology, pharmaceutical and academic organizations. It offers regulatory DDI studies, transporter screening, tranporter profiling, and custom development services. The firm's products include TransFlex Single Transporter Assay Plates,TransFlex Multi-Transporter Model Plates, and Certified Efflux Transporter Vesicles. The company was founded by Yong Huang, Pascal Druzgala and Peter G. Milner in 2007 and is headquartered in Santa Clara, CA. | Gründer | 01.01.2007 |
Renexxion LLC
 Renexxion LLC Pharmaceuticals: MajorHealth Technology Renexxion LLC is a gastrointestinal biopharmaceutical company. It develops naronapride. The company was founded by Peter G. Milner, Muralitharan Kengatharan , and Pascal J. Druzgala in 2014 and is headquartered in Menlo Park, CA. | Gründer | 01.01.2014 |
Ischemix, Inc.
 Ischemix, Inc. Pharmaceuticals: MajorHealth Technology Ischemix, Inc. is a privately-held drug development company based in an undisclosed location. The American company focuses on developing its family of cytoprotective compounds for serious diseases and conditions, with the primary focus being the development of its lead compound, CMX-2043, for the treatment of TBI. Ischemix is working to advance cytoprotective therapies. The company was founded in 1999 by Victor Shashoua, and David DeWahl has been the CEO of the company since 2013. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Peter G. Milner
| Unternehmen | Position | Ende |
|---|---|---|
Heart Metabolics Ltd.
 Heart Metabolics Ltd. BiotechnologyHealth Technology Heart Metabolics Ltd. operates as a biopharmaceutical company that engages in developing new treatments for orphan disease including cardio-metabolic diseases. The firm provides drugs to treat heart failure for hypertrophic cardiomyopathy patients. The company was founded by Michael Paul Frenneaux and Houshman Ashrafian in 2004 and is headquartered in Dublin, Ireland. | Vorstandsvorsitzender | 02.01.2015 |
| TRILLIUM THERAPEUTICS | Direktor/Vorstandsmitglied | 18.08.2011 |
| ░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
| ░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░ ░░░░░░░░░░ ░░ ░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Ausbildung von Peter G. Milner
| The University of Liverpool | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ARYX THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 14 |
|---|---|
SinuSys Corp.
SinuSys Corp. Medical SpecialtiesHealth Technology SinuSys Corp. develops medical device therapies to improve the sinus health of patients with chronic sinusitis. Its products include Vent-OS sinus dilation system, Restora steroid-eluting spacer, and SinuSys product pipeline. The company was founded by Jerome Hester and Thomas A. Schreck in 2010 and is headquartered in Palo Alto, CA. | Health Technology |
ABV LLC
 ABV LLC Investment ManagersFinance ABV LLC(Ascent Biomedical) is a venture capital firm founded in 2004 by Steven I Hochberg, Geoffrey W Smith and Steve Hochberg. The firm is headquartered in New York. | Finance |
Lifeline Technologies, Inc.
Lifeline Technologies, Inc. BiotechnologyHealth Technology Lifeline Technologies, Inc. operates as a health sciences development company which focuses on novel strategies. It offers ChoLESStolife, a non-prescription and non-synthetic cholesterol absorption inhibitor for the reduction of human cholesterol using a fat-free delivery system for soy sterols and stanols. The company was registered by Curtis A. Spilburg and Richard E. Ostlund on October 1, 2002 and is headquartered in Hendersonville, NC. | Health Technology |
| California Healthcare Institute | Health Technology |
Trillium Therapeutics ULC
 Trillium Therapeutics ULC BiotechnologyHealth Technology Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada. | Health Technology |
CV Therapeutics, Inc.
 CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | Health Technology |
| ML Laboratories Plc | Commercial Services |
AshHill Investments LLC
AshHill Investments LLC Investment ManagersFinance AshHill Investments LLC (AshHill Investments) is a venture capital firm founded in 2011. The firm is headquartered in Ft. Thomas, Kentucky. | Finance |
Armetheon, Inc.
Armetheon, Inc. Pharmaceuticals: MajorHealth Technology Armetheon, Inc. engages in medical development. It specializes in thrombosis and cardiac arrhythmias. The company was founded by Pascal J. Druzgala, Muralitharan Ken Kengatharan and Peter G. Milner in 2011 and is headquartered in Milpitas, CA. | Health Technology |
Heart Metabolics Ltd.
Heart Metabolics Ltd. BiotechnologyHealth Technology Heart Metabolics Ltd. operates as a biopharmaceutical company that engages in developing new treatments for orphan disease including cardio-metabolic diseases. The firm provides drugs to treat heart failure for hypertrophic cardiomyopathy patients. The company was founded by Michael Paul Frenneaux and Houshman Ashrafian in 2004 and is headquartered in Dublin, Ireland. | Health Technology |
Optivia Biotechnology, Inc.
Optivia Biotechnology, Inc. Pharmaceuticals: MajorHealth Technology Optivia Biotechnology, Inc. provides contract research organization offering drug transporter research services and solutions to biotechnology, pharmaceutical and academic organizations. It offers regulatory DDI studies, transporter screening, tranporter profiling, and custom development services. The firm's products include TransFlex Single Transporter Assay Plates,TransFlex Multi-Transporter Model Plates, and Certified Efflux Transporter Vesicles. The company was founded by Yong Huang, Pascal Druzgala and Peter G. Milner in 2007 and is headquartered in Santa Clara, CA. | Health Technology |
Retrotope, Inc.
 Retrotope, Inc. Pharmaceuticals: MajorHealth Technology Retrotope, Inc. operates as clinical-stage pharmaceutical company that develops drugs to treat degenerative diseases. It offers drugs and therapies to treat Parkinson’s, Alzheimer’s, mitochondrial myopathies and retinopathies diseases. The company was founded by Charles R. Cantor, Robert J. Molinari, and Mikhail S. Shchepinov in 2006 and is headquartered in Los Altos, CA. | Health Technology |
Renexxion LLC
Renexxion LLC Pharmaceuticals: MajorHealth Technology Renexxion LLC is a gastrointestinal biopharmaceutical company. It develops naronapride. The company was founded by Peter G. Milner, Muralitharan Kengatharan , and Pascal J. Druzgala in 2014 and is headquartered in Menlo Park, CA. | Health Technology |
Ischemix, Inc.
Ischemix, Inc. Pharmaceuticals: MajorHealth Technology Ischemix, Inc. is a privately-held drug development company based in an undisclosed location. The American company focuses on developing its family of cytoprotective compounds for serious diseases and conditions, with the primary focus being the development of its lead compound, CMX-2043, for the treatment of TBI. Ischemix is working to advance cytoprotective therapies. The company was founded in 1999 by Victor Shashoua, and David DeWahl has been the CEO of the company since 2013. | Health Technology |
